HCV Advocate Logo
Contact Us Site Map  
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
HCV Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 
Conference Reports

Back to Conference Reports

HEPATITIS B VIRAL RESISTANCE: MECHANISMS AND DIAGNOSIS

Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Victoria, Australia

Summary

Antiviral drug resistant mutants emerge as a function of at least six factors: the viral mutation frequency, the intrinsic mutability of the antiviral target site, the selective pressure exerted by the drug, the magnitude and rate of virus replication, the overall replication fitness of the mutant and the availability of replication space The mechanisms of nucleoside/nucleotide analogue resistance include steric hindrance, sub-optimal nucleophilic attack geometry and pyrophosphorolysis. The hepatitis B virus (HBV) is an ancient pathogen of man and has evolved a number of elegant strategies to avoid elimination from an infected host. Thus the emergence of antiviral drug resistance during the treatment of HBV infections was not surprising once nucleoside/nucleotide analogues were introduced as specific therapy. Because of the overlap of the reading frames of the HBV polymerase (Pol) with the frame-shifted hepatitis B surface antigen (HBsAg), drug-resistant mutations in the HBV Pol can directly impact on the nature of HBsAg and its function, including properties of viral neutralization. The clinical, pathological and public health importance of HBV drug-resistant mutants is now very clear and improved treatment strategies are urgently required to prevent their continued selection, otherwise inadequately treated patients and the wider community will suffer the subsequent disastrous consequences.

Key words: antiviral drug-resistance, cross-resistance, viral dynamics, replication fitness, replication space, molecular modelling, public health impact, compensatory mutations.

Back to top

2. Introduction

Professor Doug Richman has recently defined an antiviral drug as one that selects for resistance [1]. Antiviral drug resistance depends on the viral mutation frequency, intrinsic mutability of the antiviral target site, the selective pressure exerted by the drug, and the magnitude and rate of virus replication [1]. Other factors include replication fitness and replication space [2] and each of these factors will be discussed in this review. A number of clinical and virological risk factors have been identified as they pertain specifically to lamivudine and chronic hepatitis B including pre-therapy serum HBV DNA and ALT level [3, 4], inadequate HBV DNA suppression [5], duration of therapy [6, 7], viral HBsAg serotype/viral genotype [8] and body mass index [6]. These factors will be covered by Professor Fabien Zoulim.

Back to top

3. Nomenclature

There has been considerable confusion with the use of different numbering systems by particular investigators for the various mutated codons in the HBV polymerase (Pol). The reason for this confusion can be found in the fact that HBV is presently classified into 7 main genotypes (A-G) (see Table 1) based on a greater than eight percent difference in nucleotide sequence over the entire genome [9, 10]. Not all HBVs are exactly the same genomic length and the Pol is likewise unequal, due to the presence of deletions or insertions within the linker or spacer domain between the terminal protein and catalytic components of the protein (see Figure 1). To overcome this confusion, a group of investigators developed a genotype - independent numbering scheme for the HBV Pol domain [10], where the methionine (M) in the YMDD locus of the catalytic C domain of the Pol is numbered as rtM204 rather than 539, 549, 550 or 552 (see Table 1). This numbering system will be used in this paper.

Back to top

4. Detection of Drug-Resistant Mutant HBV

There are three major methods for detecting and measuring antiviral drug-resistance: genotypic assays, phenotypic methods and virtual phenotyping.

Genotypic resistance assays use DNA sequencing methods to examine the polymerase region of the HBV genome for recognizable resistance-associated mutations [11-13]. An interpretation of sequence is required (see Table 2). The line probe assay (LiPA) is based on an oligonucleotide hybridization capture system [14] which probes for previously identified subsets of resistance mutations known to occur in HBV Pol. This approach does not require an interpretation of sequence data.

Phenotypic assays typically use cell culture based methods for measuring the inhibitory concentration of an antiviral drug that reduces viral replication by at least fifty-percent (IC50) and a number of systems are available. These have been recently reviewed by Delaney and colleagues [15]. An increase in the IC50 level, an increase in resistance, or a decrease in susceptibility indicates that more drug is needed to inhibit the mutant virus in vitro relative to the reference virus. Usually a greater than ten-fold increase in IC50 is associated with "resistance" whilst a less than five-fold increase is regarded as "sensitive", and a five to ten-fold increase represents partial resistance [16].

Virtual phenotyping in the matching of polymerase sequences from a HBV strain of interest to HBV strains that have both identical or near identical sequences and a known antiviral drug phenotype which are held in a large database. A "virtual" phenotype for the test HBV strain can then be assigned by extrapolation and reported as the mean IC50 of all matches to the wild-type virus. An in-house system has been developed at the VIDRL (Virtual Virology: SeqHepB) similar to the analysis module used by Virco for the human immunodeficiency virus (HIV) [17].

Back to top

5. Patterns of Resistance and Profiles of Cross-Resistance

Six major genotypic patterns of lamivudine resistance have been described (see Table 2). In each, the rtM204 of the YMDD locus is altered. The group 2 mutation of rtM204I is the only single mutation, whilst for the other five groups other changes are detected in either the B or A domains of the HBV Pol. Many other secondary changes have been observed including rtL80V/I, rtL82M, rtT128N, rtF166L, rtL179P, rtA181T, rtT184S, rtA200V, rtV207T, rtS213T, rtS219P, rtI224S and rtL229V/M and these also are found in conjunction with the M204 V/I/S mutants [10, 15, 18].

Using transient transfection assays, antiviral cross-resistance testing for nucleoside/nucleotide analogues has been performed against the major lamivudine and famciclovir resistant mutants (see Table 3). Only adefovir and diaminopurine dioxalone (DAPD) demonstrate activity against all these mutants whilst entecavir has partial activity [15, 16, 19].

Several non-nucleoside analogue inhibitors have been developed including the phenylpropenamide derivatives AT-61 and AT-130 [20] as well as LY 582563, a novel antiviral agent from Lilly Pharmaceuticals. All of these compounds have significant antiviral activity against drug-resistant HBV [21, 22].

Back to top

6. Viral Dynamics, Replication and Mutation Rate of the Viral Polymerase

The rate of HBV virion production in vivo can influence the production of viral genetic mutants. When compared with HIV and hepatitis C virus (HCV), the HBV production rate is considerably higher. A number of groups have made estimates of HBV production and found it to be in the order of 1011 virions per day compared with 109 for HIV and HCV [23-26]. The half-life of HBV in plasma ranges from 1 to 3 days [23-26] whilst the half-life of an infected cell is 10-100 days [23-26]. With this enormous daily virion production, errors of the replication process will inevitably occur. Viral reverse transcriptases (RTs), unlike DNA polymerases, do not encode for a proof reading or editing activity that can remove a misincorporated dNTP [27]. The error rate of the HBV Pol has been calculated to occur at 10-4 per nucleotide per replication cycle [28]. Therefore, on a daily basis, approximately 1014 nucleotides are replicated with potentially 1010 base-pairing errors. When a viable mutation occurs, the expansion of the virus harbouring this mutation is predicted on the functional consequences of the mutation. In the absence of an intact immune system or other selection pressure, the faster replicating mutant would be expected to outgrow the slower viruses. This seems to be the case in the setting of a newly infected liver, but as the liver becomes fully infected, the effect of selective advantage is reduced [29], and other factors such as viral fitness and replication space become important (see below). The recent description of a pyrophosphorolysis activity for the duck HBV Pol and its potential role on drug resistance will be discussed below [30].

Back to top

7. Replication Fitness, Selection Pressure & Replication Space

The pattern and kinetics of HBV resistance to antiviral agents can be understood in terms of a balance between replication fitness, replication space and selection pressure.

(i) Replication Fitness

Differences in the phenotypic expression of antiviral drug resistant mutants based on qualitative assessment of the signal densities of the viral replicative intermediates, including cytoplasmic core-associated single-strand HBV DNA as detected by Southern hybridization (ie. yield assay), have been used by a number of investigators as an indicator of "replication fitness" [31-34]. All of these studies claimed that lamivudine resistant HBV was "replication impaired" based on in vitro data generated from transient transfection systems. In the clinical situation however, these viruses become the dominant quasispecies after only a few months of antiviral treatment, and have been associated with and linked to exacerbation of liver disease in chronically infected patients [35]. Additionally, such viruses have been shown to be associated with graft failure in transplant patients [36]. These yield assays are not true measures of viral fitness. The Darwinian definition of fitness is the ability to produce offspring in the setting of natural selection [37]. Clearly, there are differences in viral replication between mutant and wild-type HBV which play an important role in the replacement of "the less fit viral species" in patients undergoing antiviral therapy, but current in vitro assays used for studying HBV, such as transient transfections, are incapable of resolving them.

The relative replication fitness of viral mutants can be assessed using in vitro co-infection competition assays. For HIV, this approach is now regarded as the accepted method of measurement of "competence" or "fitness" [38, 39]. In these assays, by the process of Darwinian competition, there is selection of the "fittest" virus which becomes the predominant species after several rounds of replication. Recently, De Ronde and colleagues (2001) [40] have extended this approach and been able to quantify the different HIV quasispecies in vitro during one round of replication in cells using molecular beacons and real time nucleic acid sequence based amplification (NASBA). Similar studies need to be carried out for HBV and the recently described recombinant HBV baculovirus model [41] can be used to deliver replication competent genomes of both wild-type and mutant HBV to HepG-2 cells in a co-infection format (Locarnini S, Bowden S, Bartholomeusz A and Lewin S 2002, unpublished data) using molecular beacons and real-time PCR [26].

There are also in vitro assays that can describe the behaviour of HBV polymerase mutants such as the kinetics of RNA- and DNA- polymerization [42], enzyme processivity [43] and enzyme fidelity and mutation frequencies [44]. The ability of the polymerase to catalyse the incorporation of nucleotides during synthesis of cDNA products before the enzyme dissociates from the template is described as processivity whilst the ability of the polymerase to correct base-pair the template during polymerization is defined as enzyme fidelity. There have only been limited studies that have attempted to describe these enzymatic properties in HBV. Xiong and colleagues [45, 46] have used the baculovirus expressed wild-type [47] and mutant HBV polymerases to study enzyme inhibition using the active forms of nucleoside/nucleotide analogues as well as natural substrates. These studies were performed in the absence of the nucleocapsid of the virus and so may not necessarily reflect viral polymerase activity in infected cells. However, enzyme processivity of wild-type HBV polymerase has been studied in recombinant HBV nucleocapsids generated by co-expression of HBV Pol and core in the baculovirus expression system [48, 49]. The lack of published studies is a reflection of the inherent limitations of HBV cell culture systems and the technical difficulties of obtaining functionally active HBV Pol in sufficient quantities and enzymatic reliability [47].

(ii) Selection Pressure

In clinical trials of HIV drugs, most of the beneficial effect resulting from monotherapy is largely reversed within 4 weeks after initiation of treatment [50]. This reversal is directly associated with the emergence of drug-resistant mutants [51, 52]. These observations are also consistent with the existence of drug-resistant populations in patients before treatment [53] and similar populations of pre-existing lamivudine resistant HBV have been identified in drug-naive individuals [54]. Since these mutations are rarely without cost from the virological perspective [55], compromising mutations tend to survive under the pressure of selection by a second compensatory mutation that partially restores the original levels of viral replication [56]. Contrary to earlier in vitro data in which the mutant viruses were studied in the absence of selective drug pressures [33, 34, 57], Bock and colleagues [58] showed enhanced in vitro replication of the lamivudine resistant rtM204 V/I containing HBV Pol mutants when cultured in the presence of the lamivudine selection pressure. This was particularly noticeable when other mutations in the viral envelope (eg.: G145R or P120T) were also present on the same genome. These findings have important clinical and pathogenesis implications, since the viral load in serum would be expected to drop significantly when drug therapy was withdrawn [59].

(iii) Replication Space

Replication space can be understood in terms of the major transcriptional template of HBV, the covalently closed circular (ccc) DNA molecule. Using this approach, Zhang and Summers [29, 60], have defined replication space as the potential of the liver to accommodate new HBV ccc DNA molecules. The maximum capacity of ccc DNA in a liver is limited by the number of hepatocytes that can be infected and by the maximum number of ccc DNA copies per hepatocyte. In a fully infected liver, the synthesis of new ccc DNA can occur only if uninfected cells are generated by growth of the liver, hepatocyte turnover, or loss of ccc DNA from infected hepatocytes [2, 61]. In the absence of the appropriate selection pressure, an emerging virus strain can prevail over pre-existing strains via competitive out-growth only in the setting of hepatocyte turnover or ccc DNA loss [60]. Therefore, the enrichment of one species over another implies that the expanding virus has augmented its population via an expansion of ccc DNA synthesis [2]. However, if there is limited initiation of new infections, which can be the case in a chronically infected liver with minimal necroinflammatory activity [23], then the expansion of a drug-resistant mutant in the infected liver can only be possible with the creation of new replication space [60].

The emergence of drug-resistant viruses during antiviral therapy may correspond to the loss of the wild-type ccc DNA from the liver and their replacement by mutant viral ccc DNA, thereby allowing the mutant HBV to expand. Hepadnaviral ccc DNA, which is found in viral minichromosomes in the nucleus of infected hepatocytes [62, 63] appears to be quite stable and "relatively resistant" to nucleoside/nucleotide analogue therapy. In animal models and tissue cultures, treatment with single antiviral agents does not result in any appreciable loss of wild type ccc DNA molecules in hepatocytes [64, 65]. However, during antiviral combination chemotherapy experiments in vitro [66] and in vivo [67], the level of viral ccc DNA has been observed to fall significantly. Unfortunately, this key replicative form has never been eliminated by antiviral therapy [68, 69] although it can be controlled by an endogenous antiviral cytokine response [70]. Some of these discrepant observations can be explained by the fact that hepadnaviral ccc DNA exists in the liver as multiple topoisomers [62, 63] which may represent different transcriptional states reflecting complex genetic regulation [63].

Patients with chronic hepatitis B with raised serum ALT appear to have increased hepatocyte turnover [2, 60], which provides the necessary replication space for the expansion of drug-resistant mutants. Thus, in the presence of the selection pressure, the selected resistant quasispecies in the nascent virion pool can slowly replace the existing wild-type ccc DNA [61].

Back to top

8. Mechanistic Considerations

The HBV DNA polymerase gene has regions of sequence homology to other viral RTs, in particular HIV [71]. However, the multi functional nature of the HBV Pol is unique to hepadnaviruses, and can be defined by four distinct domains: a N-terminal protein that serves as the primer for RT, a spacer region of unknown function, the RT domain, and ribonuclease H [72]. The polymerase domain has been further divided into at least five subdomains designated A through E [73] and for RTs, two other domains F and G can be identified (Figure 1).

The genotypic resistance patterns found in patients with drug-resistant HBVs was discussed above (Table 2). Studies of drug-resistant mutations of HIV RT have yielded much data on the mechanisms of nucleoside/nucleotide analogue resistance [74, 75], some of which can be extended to drug-resistant HBV Pols. The structure of the HIV RT has been resolved by X-ray crystallography [76, 77]. Drawing upon the sequence homology to other viral RT including HIV, several groups have developed 3 dimensional models of HBV Pol [71, 78, 79]. Each model assumes a right-handed conformation similar to other viral reverse transcriptases with a thumb, palm and finger domains [76, 77]. Domains A, C and D are mainly involved in deoxynucleoside triphosphate (dNTP) binding and catalysis and correspond to the palm domains. Domains B and E interact with the RNA template and primer regions respectively, and are also found in the palm domain of this right-handed model [74, 75]. The C domain of the HBV Pol contains the YMDD motif which is highly conserved in other RTs [73].

Point mutations in the HIV RT that lead to nucleoside/nucleotide analogue resistance typically cluster in the vicinity of the dNTP binding site, which has a precisely configured structure. From the crystallographic data, mutations affecting the YMDD locus typically alter the ability of the dNTP binding pocket to accommodate the nucleoside/nucleotide analogue. Thus, the primary mechanism of resistance appears to be by steric hindrance within the dNTP binding pocket [74, 75]. When the methionine (M) in the YMDD motif is replaced by valine (V) or isoleucine (I), the new amino acid side-chain projects into the dNTP binding site. Steric hindrance has been demonstrated for lamivudine when it was modelled into the dNTP binding pocket of the lamivudine-resistant mutations YIDD or YVDD [74, 75, 79]. The ? branched side-group of the V or I competes against the sulphur atom of lamivudine for the same space within the binding pocket. These alterations in the dNTP binding pocket can also hinder binding of the usual D-conformation nucleoside triphosphates.

The second mechanism whereby these mutations can cause resistance has been recently recognised following a more detailed examination of these molecular models [2]. The catalytic efficiency of the enzyme is adversely affected by causing sub-optimal nucleophilic attack geometry [2]. The catalysis of the incoming dNTP to the elongating DNA strand is dependent on a precise spatial arrangement of the 5'-a- phosphate and the 3'- hydroxyl group. Alterations in the geometry of the reaction constituents can greatly diminish the efficiency of catalysis. As well as the steric hindrance encountered by lamivudine in the dNTP binding site of drug-resistant [rtM204 V/I] polymerase, the low-affinity occupation of the site by lamivudine is further compounded by this sub-optimal nucleophilic attack geometry [2] caused by the particular amino-acid substitutions [74, 75].

Other mutations associated with lamivudine-resistent HBV Pol occur outside the dNTP binding site. For example, the B domain changes rtV173L and rtL180M can occur in parallel with the rtM204V/I mutations [78, 80] as can the A domain change rtL80V/I [18].

Pyrophosphorolysis and pyrophosphate exchange are two non hydrolytic HIV RT activities that can result in the removal of newly incorporated nucleotides, thereby providing a third mechanism of nucleoside/nucleotide analogue resistance [30, 81, 82]. The ability to remove newly incorporated nucleotides during replication has important biological and clinical implications, since these reactions may serve a primer unblocking function. The role of increased primer unblocking by pyrophosphorolysis in AZT-resistance has been documented for HIV RT [81, 82]. However, this does not appear to be a mechanism by which further resistance to lamivudine can be mediated, since lamivudine-resistant HIV RT demonstrates little, if any pyrophosphorolytic activity on lamivudine-terminated DNA [83]. Similarly, drug removal by pyrophosphorolysis appears unlikely to be involved in HBV resistance to lamivudine [30]. However, drug-resistance to other antivirals could develop because of enhanced primer unblocking by either wild-type or lamivudine-resistant HBV Pol [30].

Back to top

9. HBV Pol-Env Link

The genome of HBV is organised into overlapping reading frames, with the polymerase gene overlapping the envelope gene(s). As a result of this arrangement, HBV Pol gene mutations that are selected during the course of antiviral therapy do affect the envelope proteins and so may represent potential antibody neutralization-escape and or T-cell escape mutants. Therapy with lamivudine results in mutations in the polymerase gene of which a number are associated with alterations in the neuralization or "a" determinant of the HBsAg protein [84-86] (see Table 4). In a recent study exploring the link between polymerase mutations and altered envelope antibody binding, Torresi and colleagues [87] demonstrated markedly reduced binding of anti-HBs to the following HBV mutants exhibiting rtV173L, rtM204I, rtL180M+rtM204V, rtV207I, and rtV173L+rtL180M+rtM204V mutated polymerases (Table 4). These findings raise the possibility that the selection of lamivudine resistant HBV mutants with antigenically distinct HBsAg proteins could potentially behave as vaccine escape mutants (Figure 2).

Back to top

10. Compensatory Mutations

Compensatory mutations that partly or wholly restore the level of viral fitness have been documented during therapy for HIV infections [56]. Similar scenarios have been described for HBV. Ogata and colleagues [18] first described that multiple polymerase mutations rtL80I/V (domain A) plus rtM204I (domain C) in genotype C infected patients were associated with significantly higher viral loads, increased lamivudine resistance as well as disease exacerbation.

Hadziyannis and colleagues [88] have documented that basal core promoter (BCP) and precore stop codon mutations in genotype D infected patients that are associated with HBeAg-negative chronic hepatitis B are also resistant to lamivudine (rtM204I), disease exacerbation and disease progression occurs whilst therapy is maintained.

These reports, and the observed enhanced replication of HBV in the presence of lamivudine [58], lead to the conclusion that multiple mutations that are selected for during inadequate antiviral therapy can act as compensatory mutations and have the potential to restore replication fitness.

Back to top

11. Transmissibility

The transmissibility of drug-resistant HBV mutants has now emerged as a potentially important public health issue. Thibault and colleagues [89] recently documented the transmission of lamivudine-resistant HBV (rtL180M+rtM204V) between two male homosexuals. The incubation period and clinical presentation was typical of acute viral hepatitis B, although the viral replication levels were lower during the acute phase. The patient had not previously been vaccinated against HBV but did have an uneventful recovery. This case does raise several serious public health concerns in the context of the current immunisation program that underpin the global control program for HBV infection [90].

Back to top

12. Conclusion

In conclusion, the swarm of genetic variants that can be found in any patient infected with a viral pathogen such as HBV tend to represent a mixture of viruses with varying replication fitnesses and selection advantages under the changing conditions of host-cell type, immune response or pressure from drug treatment. The fitness of the predominant population changes in response to changing selection pressures [91]. Increasing the antiviral effectiveness of therapy is accompanied by an increasing probability that drug-resistant mutants will be selected, but only up to a point [1, 92]. At high levels of antiviral activity suppressing virus replication reduces the likelihood that resistance mutations will be selected because replication is the process responsible for the emergence of the mutations [1, 92]. This key relationship can be described as a bell-shaped curve[1, 50, 93] and leads to the inevitable conclusion that no replication (NR) equates to no resistance (NR), or put another way: NR=NR .

Back to top

13. Acknowledgements

The author acknowledges the editorial assistance of Pam Nagle and Sandra Maunders. I am also grateful to Dr. Angeline Bartholomeusz for reviewing the manuscript and constructive comments and suggestions.

References

  1. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000;32:866-7.
  2. Doo E, Liang JT. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterol 2001;120:1000-1008.
  3. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002;24:173-81.
  4. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12:67-71.
  5. Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, Heinz FX, Watschinger B, Hofmann H. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000;181:2063-6.
  6. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
  7. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
  8. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-5.
  9. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503.
  10. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
  11. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
  12. Tipples A, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
  13. Bartholomew M, Jansen R, Jeffers L, Reddy K, Johnson L, Bunzendhl H, Condreay L, Tzakis A, Schiff E, Brown N. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
  14. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-7.
  15. Delaney IV WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001;12:1-35.
  16. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P, Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl- beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-2501.
  17. Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, Larder B, Kemp SD. A Mutation in the 3' Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance. J Virol 2002;76:6836-40.
  18. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 1999;59:270-6.
  19. Delaney IV WE, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini S. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001;45:1705-1713.
  20. King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L- 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1998;42:3179-86.
  21. Delaney IV WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. The phenylopropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrobial Agents & Chemotherapy 2002;(in press).
  22. Colledge D, Shaw T, Bowden S, Locarnini S, Lewin S, Wightman F, Colacino J. The purine nucleotide analogue LY582563 (mcc-478) inhibits replication of wild type and drug resistance hepatitis B virus. J Hepatol 2002;36:307A.
  23. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:4398-4402.
  24. Zeuzem S, de Man RA, P. H, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997 1997;27:431-436.
  25. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
  26. Lewin S, Ribeiro RM, Walter T, Lau GKK, Bowden DS, Locarnini S, Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1120.
  27. Brown JL, Carman WF, Thomas HC. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology 1992;15:144-8.
  28. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989;170:595-7.
  29. Zhang YY, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999;73:3616-22.
  30. Urban S, Fischer KP, Tyrrell DL. Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. Proc Natl Acad Sci U S A 2001;98:4984-9.
  31. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
  32. Melegari M, Scaglioni PP, Wands JR. Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol 1998;72:1737-43.
  33. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998;55:1567-72.
  34. Ono-Nita SK, Kato N, Shiratori Y, Lan K-H, Yohida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-1640.
  35. Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
  36. De Man RA, Bartholomeusz A, Niesters HGM, Zondervan PE, Locarnini S. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B virus: Hepatitis B Immune Globulin Escape, Famciclovir Non-Response, followed by lamivudine resistance resulting in graft loss. Journal of Hepatology 1998;29:669-675.
  37. Darwin C. On the Origin of Species by Means of Natural Selection., 1859.
  38. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 1999;73:5356-63.
  39. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC. Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69. J Virol 2000;74:10958-64.
  40. De Ronde A, van Dooren M, Van der Hoek L, Bouwhuis D, de Rooij E, Van Gemen B, de Boer R, Goudsmit J. Establishment of new transmissible and drug-sensitive Human Immunodeficiency Virus Type 1 wild types due to transmission of nucleoside analogue-resistant virus. Journal of Virology 2001;75:595-602.
  41. Delaney WEt, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998;28:1134-46.
  42. Reardon JE. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J Biol Chem 1993;268:8743-51.
  43. Back N, Nijhuis M, Keulen W, Boucher C, Oude Essink B, van Kuilenburg A, van Gennip A, Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the transverse transcriptase enzyme. EMBO 1996;15:4040-4049.
  44. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.
  45. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-1673.
  46. Xiong X, Yang H, Westland C, Zou R, Gibbs C. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000;31:219-224.
  47. Lanford RE, Notvall L, Beames B. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J Virol 1995;69:4431-9.
  48. Seifer M, Hamatake R, Bifano M, Standring D. Generation of replication competent Hepatitis B virus nucleocapsids in insect cells. J Virology 1998;72:2765-2776.
  49. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;28:3200-3208.
  50. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV infected patients. Journal of Hepatology 1999;30:536-550.
  51. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
  52. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, et al. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. Aids 1995;9:351-7.
  53. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C, Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
  54. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-6.
  55. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
  56. Ho D, Toyoshima T, Mo H, Kempf D, Norbeck D, Chen Cea. Characterisation of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetic protease inhibitor. J Virol 1994;68:2016-2020.
  57. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455.
  58. Bock C, Tillmann H, Torresi J, Klempnauer J, Locarnini S, Manns M, Trautwein C. HBV polymerase mutants with enhanced replication selected during lamivudine therapy result in sudden onset of liver failure. Gastroenterol 2002;122:264-273.
  59. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999;30:244-56.
  60. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000;74:5257-65.
  61. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
  62. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994;8:215-29.
  63. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minochromosomes. Journal of Virology 1995;69:3350-3357.
  64. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997 Dec;71(12):9392-9399 1997;71:9392-9399.
  65. Dean J, Bowden S, Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res 1995;27:171-8.
  66. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000;44:551-560.
  67. Wang Y, Luscombe C, Bowden S, Shaw T, Locarnini S. Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid. Antimicrob Agents Chemother 1995;39:556-8.
  68. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139-46.
  69. Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O, Zoulim F. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002;46:425-33.
  70. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
  71. Bartholomeusz A, Groenen L, Locarnini SA. Clinical experience with famciclovir against Hepatitis B virus and development of resistance. Intervirology 1997;40:337-342.
  72. Bartholomeusz A, Schinazi R, Locarnini S. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepatitis Reviews 1998;4:167-187.
  73. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. European Molecular Biology Organisation 1989;8:3867-3874.
  74. Sarafianos SG, Das K, Clark AD, Ding J, Boyer PL, Hughes SH, Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999;96.
  75. Gao H-Q, Boyer P, Sarafianos S, Arnold E, Hughes S. The role of steric hindrance in 3TC resistance of Human Immunodeficiency Virus type-1 reverse transcriptase. J Mol Biol 2000;300:403-418.
  76. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998;282:1669-75.
  77. Jacobo-Molina A, Ding J, Clark AD, Lu X, Tantillo C, Williams RL, Kamer G, Ferria AL, Clark P. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc National Acad of Sci, USA 1993;90:6320-6324.
  78. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
  79. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;75:4771-9.
  80. Neisters H, Honkoop P, Haasma E, de Man R, Schalm S, Osterhaus A. Identification of more than one mutation in the hepatitis B virus polymerase arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382-1385.
  81. Meyer P, Matsuura S, Mian A, So A, Scott W. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999;4:35-43.
  82. Arion D, Kaushik N, McCormick S, Borkow G, Parniak M. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processitivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998;37:15908-15917.
  83. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000;74:3579-85.
  84. Locarnini S. Hepatitis B virus surface and polymerase gene variants: potential virological and clinical significance. Hepatology 1998;27:294-297.
  85. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis [see comments]. Hepatology 1998;27:213-22.
  86. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, Neuhaus P, Gerken G. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-63.
  87. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini S, Fyfe J, Sozzi T, Jackson D. Vaccine induced anti-HBs escape mutants of hepatitis B virus arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313.
  88. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
  89. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. Aids 2002;16:131-3.
  90. Kane M. Global status of hepatitis B immunization. Lancet 1996;348:696.
  91. Holland J, De La Torre H, Steinhauer D. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992;176:1-20.
  92. Condra JH, Emini EA. Preventing HIV-1 Drug Resistance. Science and Medicine 1997;4:2-11.
  93. Richman D. Antiviral drug resistance: issues and challenges. Chichester. John Wiley & Sons, 1996.

Back to top

Back to Conference Reports


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Home

Hepatitis C Support Project

(C) 2003. Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets